Evidence map›Paper›PMID 17206281›Full record

ArticlePloS one2007

At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction.

Sanja Glisic-Milosavljevic, Jill Waukau, Parthav Jailwala, Srikanta Jana, Huoy-Jii Khoo, Hope Albertz, Jeffrey Woodliff, Marilyn Koppen, Ramin Alemzadeh, William Hagopian and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Enhanced CD4Scientific reports · 2021
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Restoring Regulatory T Cells in Type 1 Diabetes.Current diabetes reports · 2016
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Regulatory T cells in children with recently diagnosed type 1 diabetes.Indian journal of endocrinology and metabolism · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Sanja Glisic-MilosavljevicThe Max McGee National Center for Juvenile Diabetes and Human Molecular Genetics Center, Medical College of Wisconsin and the Children's Research Institute of the Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States of America.
Jill Waukau
Parthav Jailwala
Srikanta Jana
Huoy-Jii Khoo
Hope Albertz
Jeffrey Woodliff
Marilyn Koppen
Ramin Alemzadeh
William Hagopian
Soumitra Ghosh
Children's Hospital of Wisconsin · USMedical College of Wisconsin · USPacific Northwest Diabetes Research Institute · US

Funding

ZONISMIDE IN THE TREATMENT OF SEIZURES IN PATIENTSM01RR000058 · NCRR · MEDICAL COLLEGE OF WISCONSIN · PI HYDE, JAMES F · 1985 to 2006
$19.9M
NCRR NIH HHS M01 RR000058NCRR NIH HHS M01-RR00058
6 · The paper itself

Abstract

backgroundIn experimental models, Type 1 diabetes T1D can be prevented by adoptive transfer of CD4+CD25+ (FoxP3+) suppressor or regulatory T cells. Recent studies have found a suppression defect of CD4+CD25+(high) T cells in human disease. In this study we measure apoptosis of CD4+CD25+(high) T cells to see if it could contribute to reduced suppressive activity of these cells. METHODS AND

findingsT-cell apoptosis was evaluated in children and adolescent 35 females/40 males subjects comprising recent-onset and long-standing T1D subjects and their first-degree relatives, who are at variable risk to develop T1D. YOPRO1/7AAD and intracellular staining of the active form of caspase 3 were used to evaluate apoptosis. Isolated CD4+CD25+(high) and CD4+CD25- T cells were co-cultured in a suppression assay to assess the function of the former cells. We found that recent-onset T1D subjects show increased apoptosis of CD4+CD25+(high) T cells when compared to both control and long-standing T1D subjects p<0.0001 for both groups. Subjects at high risk for developing T1D 2-3Ab+ve show a similar trend p<0.02 and p<0.01, respectively. On the contrary, in long-standing T1D and T2D subjects, CD4+CD25+(high) T cell apoptosis is at the same level as in control subjects p = NS. Simultaneous intracellular staining of the active form of caspase 3 and FoxP3 confirmed recent-onset FoxP3+ve CD4+CD25+(high) T cells committed to apoptosis at a higher percentage 15.3+/-2.2 compared to FoxP3+ve CD4+CD25+(high) T cells in control subjects 6.1+/-1.7 p<0.002. Compared to control subjects, both recent-onset T1D and high at-risk subjects had significantly decreased function of CD4+CD25+(high) T cells p = 0.0007 and p = 0.007, respectively.

conclusionsThere is a higher level of ongoing apoptosis in CD4+CD25+(high) T cells in recent-onset T1D subjects and in subjects at high risk for the disease. This high level of CD4+CD25+(high) T-cell apoptosis could be a contributing factor to markedly decreased suppressive potential of these cells in recent-onset T1D subjects.

Indexed as

AdolescentApoptosisCD4-Positive T-LymphocytesChildDiabetes Mellitus, Type 1FemaleGenetic Predisposition to DiseaseHumansInterleukin-2 Receptor alpha SubunitMaleRisk FactorsT-Lymphocytes, RegulatoryT-Lymphocyte SubsetsInterleukin-2 Receptor alpha Subunit

Identifiers

PMID17206281
PMCPMC1764033
OpenAlexW2081009870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.